<DOC>
	<DOCNO>NCT00971321</DOCNO>
	<brief_summary>This trial design assess safety immunogenicity prime-boost schedule GSK Biologicals ' investigational vaccine GSK2340272A child age 6 35 month . This protocol post update follow protocol amendment 4 , March 2010 . The protocol post section impact number subject , primary secondary endpoint intervention .</brief_summary>
	<brief_title>Safety , Immunogenicity Study GSK Biologicals ' Pandemic Influenza Candidate Vaccine ( H1N1 ) ( GSK2340272A )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol Children , male female , age 6 35 month time first study vaccination . Written inform consent obtain parent ( ) LAR ( ) subject . Healthy child , establish medical history clinical examination enter study . Parent/LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Clinically virologically confirm influenza infection within six month precede study start . Planned administration vaccine 30 day prior 30 day study vaccine administration . Chronic administration immunosuppressant immunemodifying drug within three month prior enrolment study plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine History neurological disorder seizure . Acute disease and/or fever time enrolment Administration immunoglobulins and/or blood product within three month prior enrolment study , plan study . Any condition , opinion investigator , render subject unfit participation study . Child Care .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>influenza infection</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340272A</keyword>
</DOC>